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994Protective Immunity Transferred by Infusion of
Cytomegalovirus-Specific CD81 T Cells within Donor
Grafts: Its Associations with Cytomegalovirus
Reactivation Following Unmanipulated Allogeneic
Hematopoietic Stem Cell Transplantation
Xiao-Hua Luo,1 Xiao-Jun Huang,2 Kai-Yan Liu,2 Lan-Ping Xu,2 Dai-Hong Liu2Human cytomegalovirus (CMV)-specific cytotoxic T lymphocyte (CTL) immune response must be reconsti-
tuted for long-term protection against CMV relapse and disease in hematopoietic stem cell transplantation
(HSCT) recipients. We phenotypically quantitated absolute numbers of CMV-pp65 peptide-specific CTLs
(CTLCMV) in 50 related donor unmanipulated allografts infused into HLA-matched or -mismatched recipients
and examined the incidence of CMV reactivation. High CTLCMV with terminally differentiated effector
CD45RO-CD62L- cell (TEMRA) phenotype in the allografts were associated with reduced risk of CMV reac-
tivation, in the presence of sufficient CD45RO1CD62L- cell (TEM) infusion ($0.208  106/kg). Early after
transplantation, there was significant expansion of CTLCMV with the central memory CD45RO
1CD62L1
cell (TCM) phenotype when CMV was reactivated. The frequencies of CTLCMV TNaive (CD45RO
-CD62L1),
TCM, and TEM at day 90 posttransplantation and of CTLCMV TEMRA at day 60 posttransplantation were greater
in recipients with higher infusions of CTLCMV TEMRA, suggesting protective immunity transferred by infusion
of CTLCMV within allografts. Moreover, the majority of the CTLCMV identified in the recipients early after
HSCTwas of donor origin. Our findings support that measuring levels of CTLCMVand its subsets in the donor
grafts and manipulating these cells early after transplantation may help control CMV reactivation, which is
closely correlated with immune reconstitution and differentiation of CTLCMV subsets.
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Donor graftsINTRODUCTION
Human cytomegalovirus (CMV) infection remains
a challenging problem after allogeneic hematopoietic
stem cell transplantation (HSCT) [1,2]. The use of
prophylactic and preemptive antiviral chemotherapy
strategies has significantly reduced the morbidity and
mortality of CMV infection [3-5]; however, CMV-
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6/j.bbmt.2010.02.007response must be reconstituted to confer long-term
protection against CMV relapse and disease. Studies
using tetramer staining combined with fluorescent
antibodies to the variable region of the T cell receptor
and single-nucleotide DNA polymorphism analysis
suggest that CMV-specific CD81 T lymphocytes
detected in CMV-seropositive recipients of allogeneic
HSCT from CMV-seropositive donors are likely of
donor origin and expand in the recipient after antigenic
stimulus because of CMV reactivation [6,7]. Gratama
et al. [8] reported CMV-specific T lymphocytes
infused with the grafts correlated inversely with the
number of preemptive courses of ganciclovir adminis-
tered after HSCT. These reports indicate that protec-
tive immunity can be successfully transferred to
patients through infusion of donor-derived antigen-
specific CD81 CTLs within allografts if the donor
has immunity to the specific antigen.
Few immunocompromised HSCT recipients with
a CMV-specific CD81 cell level.2-10 106/L devel-
oped CMV disease [8,9]. Studies of the correlation
Table 1. Clinical Characteristics of Recipients and Donors
All patients, n 50
Acute lymphoblastic leukemia, n 10
Acute myelogenous leukemia, n 23
Biphenotypic acute leukemia, n 1
Chronic myelogenous leukemia 12
Myelodysplastic syndrome, n 4
High risk/standard risk, n* 13/37
Patient age, years, median (range) 33.5 (14-55)
Males/females, n 30/20
Donor graft composition,
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have provided inconsistent results, however [10-12].
These studies suggest that control of human CMV
infection might require the presence of functional
CMV-specific T cells, rather than the ability to recover
sufficient numbers. Although adoptive transfer of
CMV-specific T cells has shown promising results
for controlling or preventing CMV reactivation, the
most desirable phenotypic profile for T cells remains
unclear [13-16].
The foregoing findings demonstrate that the mag-
nitude of CMV-specific CD81T cell response alone is
not an appropriate predictor of clinical outcome. A
recent study [17] found that different memory T cell
subsets, defined according to phenotype, had different
functional capabilities and roles [18,19], and that
their relative contributions to the overall size of the
response may relate to overall efficacy. This led us to
propose that the general phenotype of the CMV-
specific CD81 T cell response also might be linked
to its antiviral capacity.
Based onCD45RO andCD62L surface marker ex-
pression [18-20], the following linear differentiation of
antigen-experienced CD81T cells has been proposed:
naive CD45RO-CD62L1 T (TNaive) cells, central
memory CD45RO1CD62L1 T (TCM) cells, effector
memory CD45RO1CD62L- T (TEM) cells, and
terminally differentiated effector CD45RO-CD62L-
T (TEMRA) cells. TEM and TEMRA cells can produce
high levels of perforin, whereas virus-specific TCM
cells have little direct antiviral activity, but likely serve
to replenish and sustain CD81 TEM cell populations
through secretion of interleukin-2 and proliferation.
A study of human immunodeficiency virus (HIV)
infection found a link between HIV-1 specific CD81
TEMRA cell level in early infection and control of
HIV-1 viremia [17]. Distinct patterns of CD81 mem-
ory cell subsets also might affect the risk of CMV reac-
tivation [21]. In the present study, we explored
whether immunophenotypic composition of donor
grafts, especially levels of CMV-specific CD81T cells,
was correlated with the overall potency of the response
and predicted control of CMV infection in 50 HLA-
matched or -mismatched related HSCT recipients.CD34+, 106cells/kg 2.020 (0.708-50.143)
CD3+, 108cells/kg 1.536 (0.229-3.504)
CD8+, 108cells/kg 0.589 (0.091-1.506)
CD8+pentamer+ (CTLCMV), 10
6cells/kg 0.671 (0.011-16.677)
CTLCMV CD45RO
-CD62L+ (TNaive), 10
6cells/kg 0.015 (0-0.605)
CTLCMV CD45RO
+CD62L+ (TCM),10
6cells/kg 0.008 (0-0.302)
CTLCMV CD45RO
+CD62L- (TEM), 10
6cells/kg 0.208 (0-3.324)
CTLCMV CD45RO
-CD62L- (TEMRA), 10
6cells/kg 0.177 (0-13.343)
CTLCMV indicates cytomegalovirus-pp65 peptide-specific cytologic
T lymphocyte; n, number.
*High risk: Patients with acute leukemia beyond second remission, not in
remission, or Philadelphia chromosome–positive; myelodysplastic syn-
drome–refractory anemia with excess of blasts in transformation or
myelodysplastic syndrome–acute myelogenous leukemia; chronic
myelogenous leukemia in accelerated phase or blast crisis phase; or
biphenotypic acute leukemia. Standard risk: all others.MATERIALS AND METHODS
Patients and Donors
Westudied 50 consecutive patients and their donors
who had eitherHLA-A*0201 orHLA-A*2402 alleles, in
whom the recipients with a malignant hematologic
disorder underwent unmanipulated allogeneic HSCT
from an HLA-matched or -mismatched related donor
between March 2007 and April 2008 at Peking
University Institute ofHematology. All of these patients
were CMV serologically donor-positive/recipient-positive (D1/R1) pretransplantation, and were given
both granulocyte colony-stimulating factor (G-CSF)-
primed peripheral blood grafts (G-PBs) and G-CSF–
primed bonemarrow grafts (G-BMs) at transplantation.
The HLA-mismatched transplant recipients had no
HLA-identical related or unrelated donors.
We included all of the donors typed as
HLA-A*02011 or HLA-A*24021 using high-
resolution techniques. The combined frequencies of
these 2 alleles encompass.30% of the Chinese popu-
lation [22,23]. All recipients and their donors under
HLA-matched or -mismatched related transplantation
were matched on these 2 alleles. The Institutional Re-
view Board of Peking University approved this study,
and all 50 recipients and their respective stem cell do-
nors provided written informed consent. Because of
sample limitations, CMV-specific CTL reconstitution
could be analyzed in only 44 of the recipients. Clinical
characteristics of these recipients and their donors are
summarized in Table 1.
All patients received myeloablative conditioning
and standard prophylaxis for graft-versus-host disease
(GVHD) according to HLA disparity, as reported pre-
viously [24,25]. Acute GVHD (aGVHD) treatment
was provided as described previously [26,27]. In brief,
aGVHD was treated with methylprednisolone (0.5-1
mg$kg21$d21). GVHD manifesting in the skin was
treated with a combination of methylprednisolone
and methotrexate or methotrexate alone. In patients
with inadequate or no response to primary therapy
for GVHD, 1 mg$kg21 of anti-Tac monoclonal anti-
body (Daclizumab; Roche, Basel, Switzerland) was
administered i.v. on days 1, 4, and 8, and subsequently
at 7-day intervals, for a total of 3-6 doses.
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Donors were mobilized with recombinant human
G-CSF (rhG-CSF) (Filgrastim; Kirin, Japan), 5 mg/kg
daily, injected s.c. for 5 or 6 consecutive days. Stem
cells from BM were collected on the fourth day of mo-
bilization, and peripheral blood stem cells (PBSCs)
were collected on day 5-6. The target mononuclear
cell (MNC) count was 3-4  108 per kg of recipient
weight. BM was infused to patients within 3 hours
after collection, and PBSCs were infused fresh and
unmanipulated.
Samples from grafts (G-PBs and G-BMs) were
stained with monoclonal antibodies for flow cytometry
analysis of surface antigens CD45, CD3, CD8, and
CD34. CD341 cell enumeration was performed at
Peking University People’s Hospital, as described by
Luo et al. [28]. The absolute numbers of CD31 and
CD81 T cells were calculated and divided by actual
patient weight to determine the cell dose per kg.
Data acquisition and analyses were performed using
CellQuest software (BD Biosciences, San Jose, CA).Enumeration of CMV-Specific CTLs
Venous blood samples were collected with sodium
heparin before HSCT and at 30 days, 60 days, and
90 days post-HSCT. To serve as reference samples,
venous blood samples were obtained from 12
HSCT donors before mobilization. HLA-A*0201/
NLVPMVATV (human CMV pp65 495-504) or
HLA-A*2402/QYDPVAALF (human CMV pp65
341-349) phycoerythrin-labeled Pro pentamers
(ProImmune, Oxford, United Kingdom) was added to
unfractionated whole blood at room temperature for
10 minutes. The secondary antibodies (CD8-Percp,
CD45RO-APC, and CD62L-FITC; BD Biosciences)
and corresponding isotype antibodies were added for
the final 20 minutes of incubation, followed by lysis of
red cells using ammonium chloride lysing solution.
Cells were then fixed in 1% paraformaldehyde in
phosphate-buffered saline and analyzedwithin 12hours
on a FACScan flow cytomer (BDBiosciences). After ac-
quisition of 20,000 CD81 lymphocytes (bright, low to
intermediate forward scatter, and low side scatter), the
proportion of CD81T cells binding pentamers was as-
sessed with the unstained control subtracted (Figure 1
in the supplementary data).The absolute numberof cir-
culating CMV-specific CD81 T cells was calculated
from the proportion of CD81 T cells binding pentam-
ers and the simultaneously obtained absolute CD81 T
cells count. The phenotypically distinct memory
CD81 T cell subsets were characterized by the expres-
sion of CD45RO and CD62L as well. Blood samples
from normal donors, negative for the restricting HLA
type, served as additional negative controls.
In the stem cell grafts, the number of transplanted
CMV-specific CD81 T cells/kg body weight ofrecipient was calculated from the proportion of
CD81 T cells binding pentamers plus the simulta-
neously established number of CD81T cells/kg trans-
planted. The absolute numbers of CTL subsets
(TNaive, TCM, TEM, and TEMRA) were calculated
accordingly.
CMV Testing and Preemptive Treatment
Donor/recipient serologic status was assessed by
enzyme-linked immunosorbent assay before trans-
plantation and by plasma CMV DNA testing, using
real-time polymerase chain reaction (PCR) to moni-
tor for CMV reactivation, throughout the study
period (kits purchased from Sino-American Biotech,
Beijing, China). CMV-positive patients (.6  102
copies/mL) usually received preemptive i.v. ganciclo-
vir 5 mg/kg twice daily for 10-14 days or until CMV
tests were negative. In patients with neutropenia,
2 doses of foscarnet 90 mg/kg i.v. were administered
in place of ganciclovir. All patients received prophy-
lactic ganciclovir (5 mg/kg twice daily i.v.) from day
-9 to day -2 and acyclovir (400 mg orally) from day
11 to day 1180. A patient’s first positive CMV
PCR result was considered an event for the purpose
of this analysis, and time to first positive CMV
test result was calculated from the date of HSCT
until the date of the first positive test. CMV disease
was diagnosed according to previously published
criteria [29].
Statistical Methods
Initial univariate exploration of the baseline cova-
riates was performed using the 2-sided Fisher’s exact
test, Mann-Whitney U test, or Wilcoxon’s test. To
determine which factors independently correlated
with CTLCMV content in allografts, a multivariate lin-
ear regression model was constructed using donor
characteristics including age (\or $38 years, accord-
ing to median donor age), sex, weight (\or$68.5 kg,
according to median donor weight), pregnancy,
Epstein-Barr virus serostatus, and hepatitis B virus
serostatus. Patient variables included age, sex,
underlying disease, HLA disparity, BM transplanta-
tion (BMT) disease risk, and aGVHD. The cell type
variables were CD341, CD31, CD81, CTLCMV,
CTLCMV TNaive, CTLCMV TCM, CTLCMV TEM,
and CTLCMV TEMRA. All variables that were either
statistically significant in univariate analysis or poten-
tially important with respect to CMV reactivation (eg,
content of CTLCMV and its subsets in donor grafts)
were included in final models. The cell type variables
were included with a cutoff at the 50th percentile.
GVHD was modeled as a time-varying covariate.
The covariates in the final model were evaluated for
collinearity, using the variance inflation factor. Statis-
tical analyses were done with Stata 10.0 (Stata Corp,
Biol Blood Marrow Transplant 16:994-1004, 2010 997Protective immunity through infusion of CMV-specific CTLs within allograftsCollege Station, TX) and GraphPad Prism software
5.01 (GraphPad, San Diego, CA).RESULTS
More CTLCMV Cells in G-PBs Compared
with G-BMs
Of the total CD81 T cell population, a median of
0.48% (0-7.52%) were pentamer-positive in G-BMs,
compared with 1.165% (0-22.22%) in G-PBs. No
pentamer-positive T cells were detected in 14 G-BMs
and 1 G-PBs. G-PBs had higher proportions of
CTLCMV and CD45RO
-CD62L- (TEMRA) (P \.001
and .03, respectively), whereas G-BMs had a higher
proportion of CD45RO-CD62L1 (TNaive) (P 5 .003)
(Table 2).
Onmultivariate linear regression analysis, only do-
nor age was negatively associated with CTLCMV con-
tent in allografts (b, -1.638; 95% confidence interval
[CI], -3.116 to -0.159; P 5 .031; data not shown);
thus, this covariate was included in the subsequent
analysis for CMV reactivation. Other premobilization
donor parameters (ie, sex, weight, pregnancy, hepatitis
B virus serostatus, and Epstein-Barr virus serostatus)
were not associated with CTLCMV content differences
in allografts.
CMV Reactivation During the First 100 Days
after HSCT
A total of 632 CMV-DNA PCR assays were per-
formed during the first 100 days after HSCT, with
a median of 11 assays per patient (range, 2-26). An
initial positive CMV-DNA was detected in 31
patients (62%) at a median of 31 days after HSCT
(range, 4-68 days). The crude incidence of CMV re-
activation during this period were similar among pa-
tients across age, sex, underlying disease, steroid use,
and BMT disease risk group (Table 3). Covariates
associated with increased CMV-PCR positivity after
HSCT were recipients of HLA-mismatched HSCT
(P 5 .004) and those who experienced grade II-IV
aGVHD (P 5 .049). There was no significant differ-
ences in graft composition, including CTLCMVTable 2. Graft Product Composition
Cell Type Bone Marrow G-BM,
CD34+, 106/kg 0.67 (0.12-7.31)
CD3+, 108/kg 0.15 (0.06-1.23)
CD8+, 108/kg 0.05 (0.02-0.54)
CD8+pentamer+(CTLCMV), 10
6/kg 0.01 (0-0.81)
CTLCMV CD45RO
-CD62L+ (TNaive, %) 7.86 (0-55.43)
CTLCMV CD45RO
+CD62L+ (TCM, %) 3.49 (0-39.33)
CTLCMV CD45RO
+CD62L- (TEM, %) 40.00 (3.13-94.15
CTLCMV CD45RO
-CD62L- (TEMRA, %) 30.17 (0.14-78.57
CTLCMV indicates cytomegalovirus-pp65 peptide-specific cytologic T lymphoccontent, between patients with or without CMV
reactivation (P 5 .38-.94).CTLCMV TEMRA and TEM in Donor Grafts
Correlates with Risk of CMV Reactivation
Our multivariate proportional hazards model
included donor age, donor–recipient HLA mismatch
or match, aGVHD (grade 0-I vs II-IV) as a time-
varying covariate, and graft composition (ie, CTLCMV
TNaive, CTLCMV TCM, CTLCMV TEM, and CTLCMV
TEMRA). CTLCMV was excluded because of marked
colinearity in this model (variance inflation factor
.10), and because CTLCMV was not significant in
multivariate analysis (P 5 .593), even after the exclu-
sion of its subsets (P 5 .795). In multivariate analysis
(Table 4), HLA-matched (adjusted hazard ratio
[HR], 0.212; 95%CI, 0.078-0.579; P5 .002) remained
significantly associated with CMV reactivation.
CTLCMV TEM and CTLCMV TEMRA in allografts be-
came significant for CMV reactivation in the adjusted
model (adjusted HR, 4.386; 95% CI, 1.095-17.573;
P 5 .037 and 0.233; 95% CI, 0.065-0.831; P 5 .025,
respectively).
Most of the CMV-specific CD81 T cells in donor
grafts displayed either a TEMRA or a TEM phenotype.
Thus, there was a close and inverse correlation
between the two in the proportions of G-PBs and
G-BMs (r 5 0.57, P\ .01 and r 5 0.46, P 5 .046,
respectively; Figure 2 in the supplementary data), but
a positive correlation between the two in the absolute
numbers of total grafts (r 5 0.62, P\ .01). This is
a classic example of confounding, because higher
TEMRA infusions were more likely in patients with
higher TEM infusions at transplantation; thus, the
crude univariate analysis for subsets of CTLCMV was
severely confounded. In a separate analysis, we com-
pared the absolute numbers of TEMRA cells infused
in patients with or without CMV reactivation accord-
ing to TEM content in allografts (above median or vice
versa).We compared absolute numbers of TEMRA cells
in the same way. Figure 1 shows that patients without
CMV reactivation had more CTLCMV TEMRA infused
at transplantation (P5 .042). In contrast, no differenceG-PB PBSCs G-BM,G-PB P
1.27 (0.16-42.83) <.001
1.31 (0.08-3.37) <.001
0.49 (0.03-1.39) <.001
0.55 (0-16.68) <.001
1.04 (0-50.91) .003
1.63 (0-66.67) .56
) 42.44 (0-96.28) .48
) 41.84 (0-100) .03
yte.
Table 3. Characteristics of Crude CMV Reactivation to Day
+100 Post-HSCT
Characteristics n
CMV
reactivation, n % P
Total 50 31 62
Recipient age .61
<35 years 26 17 65.38
$35 years 24 14 58.33
Recipient sex .41
Female 20 11 55.00
Male 30 20 66.67
Primary disease .61
Acute leukemia* 33 22 66.67
Chronic myelogenous leukemia 12 6 50.00
Other† 5 3 60.00
HLA match .004
Mismatched donor 34 26 76.47
Matched donor 16 5 31.25
BMT disease
risk group
.53
Standard risk 37 22 59.46
High risk 13 9 69.23
Acute GVHD .049
Grade II-IV 13 11 84.62
None or grade I 37 20 54.05
Steroid therapy
(# day 100)
.36
>0#1 mg/kg/day 45 29 64.44
>1 mg/kg/day 5 2 40.00
Graft composition
CD34+ <2.020  106/kg 25 14 56.00 .38
CD34+ $2.020  106/kg 25 17 68.00
CD3+ <1.536  108/kg 25 16 64.00 .77
CD3+ $1.536  108/kg 25 15 60.00
CD8+ <0.589  108/kg 25 16 64.00 .77
CD8+ $0.589  108/kg 25 15 60.00
CTLCMV <0.671  106/kg 25 16 64.00 .77
CTLCMV $0.671  106/kg 25 15 60.00
CTLCMV TNaive <0.015  106/kg 24 15 62.50 .94
CTLCMV TNaive $0.015  106/kg 26 16 61.54
CTLCMV TCM <0.008  106/kg 25 15 60.00 .77
CTLCMV TCM $0.008  106/kg 25 16 64.00
CTLCMV TEM <0.208  106/kg 25 15 60.00 .77
CTLCMV TEM $0.208  106/kg 25 16 64.00
CTLCMV TEMRA <0.177  106/kg 25 17 68.00 .38
CTLCMV TEMRA $0.177  106/kg 25 14 56.00
CTLCMV indicates cytomegalovirus-pp65 peptide-specific cytologic T
lymphocyte; CMV, cytomegalovirus; GVHD, graft-versus-host disease;
HSCT, hematopoietic stem cell transplantation.
*Acute lymphoblastic leukemia and acute myelogenous leukemia.
†Biphenotypic acute leukemia and myelodysplastic syndrome.
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These findings suggest that the TEM level might be as
crucial as TEMRA level in influencing risk of CMV
reactivation.Table 4. Proportional Hazards Modeling of the Risk of CMV React
Characteristic
Donor age $38 years
HLA-matched donor
Acute GVHD grade II-IV
Graft composition
CTLCMV TNaive: CD45RO
+CD62L- $0.015  106/kg
CTLCMV TCM: CD45RO
-CD62L+ $0.008  106/kg
CTLCMV TEM: CD45RO
+CD62L+ $0.208  106/kg
CTLCMV TEMRA: CD45RO
-CD62L- $0.177  106/kg
CTLCMV indicates cytomegalovirus-pp65 peptide-specific cytologic T lymphocy
matopoietic stem cell transplantation.CTLCMV Infusion at Transplantation and
CTLCMV Reconstitution after HSCT
CTLCMV reconstitution was prospectively moni-
tored by immunophenotyping in 44 patients. Absolute
counts of CTLCMV and its subsets were calculated at
regular intervals (days 130, 160, and 190), whereas
donor blood samples were evaluated at day 23 before
mobilization as controls. The absolute numbers of
CTLCMV and its subsets after HSCT were compared
in patients with or without CMV reactivation
(Figure 2). The absolute numbers of CTLCMV with
TCM phenotype were significantly higher at day 130
and day 160 post-HSCT in patients with CMV reac-
tivation (P\.05). No statistically significant difference
in the percentage of circulating CTLCMV subsets was
found between the 2 groups (Figure 3 in the
supplementary data). The absolute counts of CD81
T cells and CTLCMV were not statistically different
between the 2 groups (Figure 2B and C); however,
analysis of the correlation between CTLCMV reconsti-
tution and CTLCMV TEMRA input showed higher
numbers of CTLCMV TNaive, CTLCMV TCM, and
CTLCMV TEM in peripheral blood at day 190 and
CTLCMV TEMRA at day 160 when HSCT recipients
received more CTLCMV TEMRA cells in allografts
(P\.05; Figure 3).Most CTLCMV Identified in the Recipient Early
after HSCT Were of Donor Origin
To determine whether CTLCMV originate from
donor cells or from recipient cells, the percentages of
CTLCMV and CMV DNA copies were calculated for
each post-HSCT sample time point. Recipients A
and B underwent human CMV D1/R1 HLA-
mismatched related donor allogeneic HSCT. Both
recipients were HLA-A*0201–positive, and both
donors were HLA-A*2402–positive. HLA-A*0201/
NLVPMVATV pentamer was used to trace CTLCMV
from recipients, and HLA-A*2402/QYDPVAALF
pentamer was used to do so from donors. Figure 4
shows that most CTLCMV originated from donors
early post-HSCT. CTLCMV from recipients remained
at low levels until day 1180, whereas CTLCMV from
donors decreased slowly to its lowest point at dayivation after Allogeneic HSCT
Multivariate HR (95% CI) P
0.799 (0.346-1.848) .600
0.212 (0.078-0.579) .002
0.996 (0.985-1.007) .450
0.840 (0.299-2.361) .741
0.799 (0.250-2.559) .706
4.386 (1.095-17.573) .037
0.233 (0.065-0.831) .025
te; GVHD, graft-versus-host disease; CMV, cytomegalovirus; HSCT, he-
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Figure 1. Relationship between TEMRA and TEM in allografts and CMV
reactivation after HSCT. (A) The absolute numbers of TEMRA in allografts
were significantly higher in patients with CMV reactivation in the pres-
ence of sufficient infusion of TEM ($0.208  106/kg). (B) The absolute
numbers of TEM in allografs were not significantly different in patients
with CMV reactivation and those without CMV reactivation, regardless
of the TEM content infused. Only significant P values are shown. ‘‘High’’
and ‘‘low’’ were introduced as above and below the median value,
respectively (TEMRA, 0.177  106/kg; TEM, 0.208  106/kg).
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Figure 2. Expansion of CTLCMV TCM cells on CMV reactivation
post-HSCT. Using flow-based frequency enumeration and absolute lym-
phocyte counts, absolute numbers of CTLCMV cells and subsets were
calculated for healthy donors (n 5 17) and HSCT recipients (n 5 44)
at regular intervals on days 130, 160, and 190. (A) The CTLCMV
with TCM phenotype was significantly higher at days 130 and 160
post-HSCT in patients with CMV reactivation compared with patients
without CMV reactivation. (B and C) The absolute counts of CD81 T
cells and CTLCMV were not statistically significantly different between
the 2 groups. Bars indicate median values. Only significant P values are
shown.
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enced CMV reactivation between day 130 and day
160, and subsets of CTLCMV differed between donors
and recipients.DISCUSSION
Even in the antiviral era, CMV serostatus is a po-
tent predictor of both CMV disease and death after
HSCT [30]. CMV disease has been reported in
17.6% of D1/R1, 20.9% of D-R1, 5.3% of D1/R-,
and 1.1% of D-/R- HSCTs [1]. When selecting
donors, a CMV-seropositive donor to a CMV-
seropositive recipient is clearly preferable, aided by in-
creased levels of multifunctional CMV-specific T cells
[30]. In this regard, evaluation of CTLCMV in donor
grafts provides the most direct assessment of donor
immunity to CMV antigen transferred to recipients.Like other biologic markers, CTLCMV can be
influenced by numerous factors. In elderly individuals,
seropositivity for human CMV leads to the develop-
ment of oligoclonal populations of CMV-specific
CTLs. These CMV-specific CTLs have a highly
polarized membrane phenotype, typical of effector
memory cells [31]. Moreover, the majority of the clon-
ally expanded virus-specific CD81 cells in the elderly
are dysfunctional [32,33], explaining our finding that
elderly donors had few CTLCMV TNaive in G-PBs.
Several previous studies have presented persuasive
evidence that CD81 CTLs play an important role
in controlling human CMV infection [8,9,12].
Comparable clinical trials using CTLCMV infusions
have demonstrated the safety and efficacy of
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[13,15,34]. However, in line with other reports
[10-12], univariate and multivariate analyses revealed
no significant relationship between frequency of
CTLCMV and CMV reactivation. This finding leaves
open the possibility that other measurable aspects of
CTLCMV response, including the contribution of key
CD81 memory T cell subsets, could be linked to
control of CMV. We found that a high number of
infused CTLCMV TEMRA is conversely correlated
with the risk of early CMV reactivation after
allogeneic HSCT with sufficient CTLCMV TEM inthe allograft. Both TEM and TEMRA are effector
memory cells for virus infection, and CD81 TEMRA
cells have greater cytotoxic function than CD81
TEM cells [35,36]. Most evidence suggests that
less-differentated or interleukin-2–producing poly-
functional cells are superior with respect to memory
T cell function. Naı¨ve or central memory CD81
T cells confer superior antitumor/antivirus immunity
compared with effector memory T cells [37-40];
however, studies have shown that CD45RO and
CD45RA of memory CD81 T cells are
interchangeable [41,42]. CD45RA1 expression has
been shown to be regulated upon antigenic
stimulation, CD81 as CD45RA1 T cell clones
become CD45RO1, and then gradually reacquire
CD45RA expression. The proliferation of all CMV
tetramer-staining cells in long-term carriers suggests
that these revertant memory cells can proliferate per-
fectly well [43], and that at least some TEMRA cells
are able to upregulate telomerase activity [44]. In addi-
tion, in our HSCT setting, HSCs may promote the
expansion and function of adoptively transferred
antigen-specific CD81 T cells, a process not affected
by the activation state of transferred T cells [45]. A
study of 18 recipients receiving T cell–depleted grafts
(some with later T cell add-back) found an association
between lower numbers of differentiated CMV-
specific donor cells and decreased recipient CMV re-
activation [46]. The difference possibly could result
from characteristic changes in T cells within allografts
after G-CSF stimulation (vs T cells from donor
peripheral blood before HSCT) [47,48], but more
likely results from much higher T cell infusions
including CTLCMV, without in vitro T cell
depletion, in our HSCT protocol. This finding
indicates that CTLCMV TEMRA in donor grafts play
a role in the immune control of CMV reactivation
after HSCT.
Regular monitoring of immune reconstitution
demonstrated significantly increased circulating
CTLCMV TCM, but not CTLCMV TEMRA or its other
subsets, in samples obtained at day 130 and day 160
post-HSCT from recipients with CMV reactivation
(on median day 131). A possible explanation for this
finding is that TEMRA may serve as backup for a func-
tional subset of CTLCMV, which responds to CMV
infection, and so CTLCMV TEMRA in peripheral blood
is not associated with CMV reactivation. As a matter of
fact, virus-specific CTL TCM can expand adequately
on virus encounter, sustain TEM and TEMRA cell
populations, and control virus infection. This, it is
likely that the TEMRA cells are ready to rapidly inter-
vene on reencounter with antigen, whereas precursor
cells will expand and ensure continuous replenishment
of the effector cell pool [49]. Whether the reduced
risk of virus infection is the result of high CTLCMV
TEMRA content in donor grafts, increased circulating
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however. Investigate a possible correlation between
input of CTLCMV TEMRA cells and reconstitution of
CTLCMV TCM cells early post-HSCT would be of
interest.
Donor graft is an important source of hematopoi-
etic cells that not only give rise to neutrophils, natural
killer cells, dendritic cells, monocytes/macrophages
and B cells, but also provide an important source ofT cells, because de novo recovery of T cells (from
hematopoietic cells) early after HSCT is inadequate.
CMV-specific CD81 T cell regeneration has been
reported to depend on the size of the T cell input,
but to not be a consequence of nonspecific
lymphopenia-driven expansions of CD31 and CD81
T cell compartments [50,51]. Consistent with this
and other reports [6,7], most CTLCMV cells detected
in our patients early after HSCT were from donors
1002 Biol Blood Marrow Transplant 16:994-1004, 2010X.-H. Luo et al.with some persistent recipient CTLs, illustrating the
transfer and expansion of CMV-specific donor T cells.
Pretransplantation, CMV-specific T cells protect
recipients of T cell–depleted grafts against CMV-
related complications [52], whereas infusion of unma-
nipulated grafts without in vitro T cell depletion using
our HSCT protocol might compromise the role of
recipient CTLs. Thus, the model for protection
from CMV infection after HSCT should focus on
the antigen-expansion or direct effect of these donor
CTLCMV cells.
We found higher frequencies of CTLCMV TNaive,
TCM, and TEM at day 190 and CTLCMV TEMRA at
day 160 post-HSCT in recipients with higher
CTLCMV TEMRA cell infusions. The association
between CTLCMV TEMRA and CTLCMV TEM in
donor grafts suggests that infusion of CTLCMV
TEMRA cells helps accelerate immune recovery of
CTLCMV and its subsets, and then helps control
CMV reactivation. Furthermore, accumulating data
suggest that CTLCMV TEMRA are by no means termi-
nally differentiated, and the reverse situation may hold
for memory CD81 T cells [36,53]. Northfield et al.
[17] showed that HIV-1–specific CD81 T cells were
phenotyped in the early phase of infection, and that
a larger number of HIV-1–specific CD81 TEMRA
was associated with a lower future viral load set point.
These authors did not continuously examine the HIV-
1–specific CD81 T cell response, however. A study of
CMV infection found that CMV-specific TEMRA
contributed to immunity not only through direct
execution of effector functions, but also by yielding
progeny in situations of viral reinfection or reactiva-
tion [44]. Questions pertaining to a similar reverse
situation in CTLCMV cells of HSCT recipients
remains to be answered [21]. Higher numbers of
CD81 TEMRA cells infused at transplantation could
yield progeny after CMV reactivation, resulting,
when accompanied by sufficient CD81 TEM cell infu-
sion, in better control of virus infections. This result
differs from findings in most adoptive immunother-
apies with mixtures of CD62L1 and CD62L- cells
[54,55], and more extensive investigations are needed
to elucidate the underlying biological mechanisms.
The immune response to a complex pathogen,
such as CMV, involves a large number of components,
with different individuals responding to different epi-
topes. Although the response to pp65 may be promi-
nent in HLA-A2– or HLA-A24–positive individuals,
other viral epitopes, such as IE-1, can contribute as
well, and in the context of other restriction elements
may even predominate [56,57].
One further issue of relevance for the use of de-
fined epitopes in an adaptive immunotherapy strategy
must be the role of major histocompatibility class II
restricted T helper cell responses. Although not all
CD8 cell responses have the same dependence onT cell help, efficient CD4 T cell responses may none-
theless be required for optimal and long-termmemory
responses [19]. Further studies of IE-1–specific CTLs
and human CMV-specific CD41 cells within donor
grafts could help elucidate their role in CMV
reactivation after HSCT. Of note, T cell responses
occur following primary infection selection of T cells
into memory and long-term maintenance [58]. The
level of antigen stimulation may play a role in the phe-
notype of the reactive cells. In this respect, an inverse
correlation between viral load and the frequencies of
CMV-specific CTLs might be expected. Indeed,
we found no significant associations in phenotype
between them (data not reported), similar to previous
studies [10-12]. An analysis of the interplay between
viral burden and size of the CMV-specific CD81
T cell response requires simultaneous analysis of its
diversity, however. Both the peak and duration of
viremia can be evaluated only discontinuously in the
population.
In summary, our data suggest that the CTLCMV
TEMRA content of donor grafts can predict the risk of
CMV reactivation after HSCT in the presence of suf-
ficient TEM cell infusion, which is closely correlated
with the immune reconstitution and differentiation
of CTLCMV subsets. Protective immunity to CMV
transferred duringHSCT is determined by the charac-
teristics of CTLCMV cells within donor grafts. These
results have important implications for adoptive cell
therapy and vaccine design for the control of CMV
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